Dynamic HER2 Switch Discovered in Circulating Breast Cancer Cells
MGH researchers have found that breast tumors grown in mice are effectively suppressed by treating them with a combination of chemotherapy and Notch inhibitors
Safe Care CommitmentGet the care you need even during COVID-19.Learn more
Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.
Clinical Interests:
Treats:
Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-6500
Phone: 617-724-4800
Fax: 617-643-0589
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
View my most recent publications at PubMed
Select Publications:
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and the only hospital to be recognized in all 16 specialties assessed by U.S. News & World Report.
MGH researchers have found that breast tumors grown in mice are effectively suppressed by treating them with a combination of chemotherapy and Notch inhibitors